NS5a GT5
Download full data set for GT5
Daclatasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 0.005 | 1x | likely susceptible | | 1,2,4 | 0.003 -0.019 (4) |
| L28I | | | | | 3 | EASL 2016 guidelines |
| M28T | | | | | | |
| M28A | | | | | | |
| M28S | | | | | | |
| M28V | | | | | | |
| M28G | | | | | | |
| Q30D | | | | | | |
| Q30E | | | | | | |
| Q30G | | | | | | |
| Q30H | | | | | | |
| Q30K | | | | | | |
| Q30L | | | | | | |
| Q30R | | | | | | |
| Q30S | | | | | | |
| Q30T | | | | | | |
| Q30Y | | | | | | |
| L31F | 6.9 | 1438x | resistance likely | | 1, 2,5 | |
| L31I | | | | | | |
| L31M | | | | | | |
| L31P | | | | | | |
| L31V | 2.2 | 458x | resistance likely | | 1,3,5 | |
| P32L | | | | | | |
| K56R | 0.012 | 3x | likely susceptible | | 1,5 | |
| P58S | | | | | | |
| A92P | | | | | | |
| T93A | | | | | | |
| T93C | | | | | | |
| T93F | | | | | | |
| T93H | | | | | | |
| T93L | | | | | | |
| T93N | | | | | | |
| T93S | | | | | | |
| L31F+K56R | 39.3 | 8188x | resistance likely | | 1,5 | |
| L31V+K56R | 29.4 | 6125x | resistance likely | | 1,5 | |
| Q30D+Y93N | | | | | | |
| Q30H+Y93H | | | | | | |
| Q30R+L31M | | | | | | |
| Q30R+H58D | | | | | | |
| L31M+H58D | | | | | | |
| L31M+Y93H | | | | | | |
| 1. Wang et al. (2014) AAC 58(9):5155-5163 |
| 2. Daklinza Canadian Product Monogram |
| 3. EASL Guidelines 2106 |
|
| 4. FDA NDA Microbiology Virology Reviews_Daklinza_206843Orig1s000MicroR |
Elbasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | | | | | | |
| L28I | | | | | | |
| M28T | | | | | | |
| M28A | | | | | | |
| M28S | | | | | | |
| M28V | | | | | | |
| M28G | | | | | | |
| Q30D | | | | | | |
| Q30E | | | | | | |
| Q30G | | | | | | |
| Q30H | | | | | | |
| Q30K | | | | | | |
| Q30L | | | | | | |
| Q30R | | | | | | |
| Q30S | | | | | | |
| Q30T | | | | | | |
| Q30Y | | | | | | |
| L31F | | | | | | |
| L31I | | | | | | |
| L31M | | | | | | |
| L31P | | | | | | |
| L31V | | | | | | |
| P32L | | | | | | |
| K56R | | | | | | |
| P58S | | | | | | |
| A92P | | | | | | |
| T93A | | | | | | |
| T93C | | | | | | |
| T93F | | | | | | |
| T93H | | | | | | |
| T93L | | | | | | |
| T93N | | | | | | |
| T93S | | | | | | |
| L31F+K56R | | | | | | |
| L31V+K56R | | | | | | |
| Q30D+Y93N | | | | | | |
| Q30H+Y93H | | | | | | |
| Q30R+L31M | | | | | | |
| Q30R+H58D | | | | | | |
| L31M+H58D | | | | | | |
| L31M+Y93H | | | | | | |
Ledipasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 0.075 | 1x | likely susceptible | | 2,3 | |
| L28I | | | | | | |
| M28T | | | | | | |
| M28A | | | | | | |
| M28S | | | | | | |
| M28V | | | | | | |
| M28G | | | | | | |
| Q30D | | | | | | |
| Q30E | | | | | | |
| Q30G | | | | | | |
| Q30H | | | | | | |
| Q30K | | | | | | |
| Q30L | | | | | | |
| Q30R | | | | | | |
| Q30S | | | | | | |
| Q30T | | | | | | |
| Q30Y | | | | | | |
| L31F | | | | | | |
| L31I | | | | | | |
| L31M | | | Resistance Possible | yes | 1 | BL RAV asso VF |
| L31P | | | | | | |
| L31V | | | | | | |
| P32L | | | | | | |
| K56R | | | | | | |
| P58S | | | | | | |
| A92P | | | | | | |
| T93A | | | | | | |
| T93C | | | | | | |
| T93F | | | | | | |
| T93H | | | | | | |
| T93L | | | | | | |
| T93N | | | | | | |
| T93S | | | | | | |
| L31F+K56R | | | | | | |
| L31V+K56R | | | | | | |
| Q30D+Y93N | | | | | | |
| Q30H+Y93H | | | | | | |
| Q30R+L31M | | | | | | |
| Q30R+H58D | | | | | | |
| L31M+H58D | | | | | | |
| L31M+Y93H | | | | | | |
| | | | | | |
| 1. Harvoni US Product Label |
| 2. Guofeng Cheng, EASL 2013, Amsterdam, Netherlands. P308 |
| 3. FDA NDA Microbilogy Virology Reviews_Harvoni_205834Orig1s000Micror |
Ombitasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 0.003 | 1x | likely susceptible | | 2 | |
| L28I | 0.07 | 79x | resistance likely | | | |
| M28T | | | | | | |
| M28A | | | | | | |
| M28S | | | | | | |
| M28V | | | | | | |
| M28G | | | | | | |
| Q30D | | | | | | |
| Q30E | | | | | | |
| Q30G | | | | | | |
| Q30H | | | | | | |
| Q30K | | | | | | |
| Q30L | | | | | | |
| Q30R | | | | | | |
| Q30S | | | | | | |
| Q30T | | | | | | |
| Q30Y | | | | | | |
| L31F | 0.26 | 289x | resistance likely | | | |
| L31I | | | | | | |
| L31M | | | | | | |
| L31P | | | | | | |
| L31V | 0.22 | 243x | resistance likely | | | |
| P32L | | | | | | |
| K56R | | | | | | |
| P58S | | | | | | |
| A92P | | | | | | |
| T93A | | | | | | |
| T93C | | | | | | |
| T93F | | | | | | |
| T93H | | | | | | |
| T93L | | | | | | |
| T93N | | | | | | |
| T93S | | | | | | |
| L31F+K56R | | | | | | |
| L31V+K56R | | | | | | |
| Q30D+Y93N | | | | | | |
| Q30H+Y93H | | | | | | |
| Q30R+L31M | | | | | | |
| Q30R+H58D | | | | | | |
| L31M+H58D | | | | | | |
| L31M+Y93H | | | | | | |
| 1. Krishnan et al., (2015) AAC 59:979-987 |
| 2. Viekira Pak US Product Label |
Pibrentasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 0.0014 | 1x | likely susceptible | | 1,2 | |
| L28I | 0.00098 | 1.1x | likely susceptible | | 1,2 | |
| M28T | | | | | | |
| M28A | | | | | | |
| M28S | | | | | | |
| M28V | | | | | | |
| M28G | | | | | | |
| Q30D | | | | | | |
| Q30E | | | | | | |
| Q30G | | | | | | |
| Q30H | | | | | | |
| Q30K | | | | | | |
| Q30L | | | | | | |
| Q30R | | | | | | |
| Q30S | | | | | | |
| Q30T | | | | | | |
| Q30Y | | | | | | |
| L31F | 0.0019 | 2.1x | likely susceptible | | 1,2 | |
| L31I | | | | | | |
| L31M | | | | | | |
| L31P | | | | | | |
| L31V | 0.00075 | 0.8x | likely susceptible | | 1,2 | |
| P32L | | | | | | |
| K56R | | | | | | |
| P58S | | | | | | |
| A92P | | | | | | |
| T93A | | | resistance possible | yes | 3 | |
| T93C | | | | | | |
| T93F | | | | | | |
| T93H | | | | | | |
| T93L | | | | | | |
| T93N | | | | | | |
| T93S | | | | | | |
| L31F+K56R | | | | | | |
| L31V+K56R | | | | | | |
| Q30D+Y93N | | | | | | |
| Q30H+Y93H | | | | | | |
| Q30R+L31M | | | | | | |
| Q30R+H58D | | | | | | |
| L31M+H58D | | | | | | |
| L31M+Y93H | | | | | | |
| 1. Ng TI, et al. 2017. Antimicrobial agents and chemotherapy 61: e02558-16 https://doi.org/10.1128/ AAC.02558-16. |
| 2. FDA Microbiology Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000MicroR.pdf |
| 3. Asselah T, et al. 2018. Journal of Hepatology 68: S39 |
Velpatasvir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Replication Fitness (5) | Reference | Comments |
| WT (SA13) | 0.021-0.054 | 1x | likely susceptible | | | 2,1 | |
| L28I | | | | | | | |
| M28T | | | | | | | |
| M28A | | | | | | | |
| M28S | | | | | | | |
| M28V | | | | | | | |
| M28G | | | | | | | |
| Q30D | | | | | | | |
| Q30E | | | | | | | |
| Q30G | | | | | | | |
| Q30H | | <2.5x | likely susceptible | | | 5 | |
| Q30K | | <2.5x | likely susceptible | | | 5 | |
| Q30L | | <2.5x | likely susceptible | | | 5 | |
| Q30R | | <2.5x | likely susceptible | | | 5 | |
| Q30S | | <2.5x | likely susceptible | | | 5 | |
| Q30T | | <2.5x | likely susceptible | | | 5 | |
| Q30Y | | | | | | | |
| L31F | | <2.5x | likely susceptible | | | 5 | |
| L31I | | >2.5 - 100x | resistance possible | | | 3,4 | VEL RAS (4) |
| L31M | | <2.5x | likely susceptible | | | 5 | |
| L31P | | unfit | | | 1.4 | | |
| L31V | | <2.5x | likely susceptible | | | 5 | |
| P32L | | <2.5x | likely susceptible | | | 5 | |
| K56R | | | | | | | |
| P58S | | <2.5x | likely susceptible | | | 5 | |
| A92P | | | | | | | |
| T93A | | | | | | | |
| T93C | | <2.5x | likely susceptible | | | 5 | |
| T93F | | <2.5x | likely susceptible | | | 5 | |
| T93H | | <2.5x | likely susceptible | | | 5 | |
| T93L | | <2.5x | likely susceptible | | | 5 | |
| T93N | | <2.5x | likely susceptible | | | 5 | |
| T93S | | <2.5x | likely susceptible | | | 5 | |
| L31F+K56R | | | | | | | |
| L31V+K56R | | | | | | | |
| Q30D+Y93N | | | | | | | |
| Q30H+Y93H | | | | | | | |
| Q30R+L31M | | | | | | | |
| Q30R+H58D | | | | | | | |
| L31M+H58D | | | | | | | |
| L31M+Y93H | | | | | | | |
| 1 Cheng G et al. Journal of Hepatology 2013;58:S484-S5. |
| 2. Epclusa US Product Label. July 2016 |
| 3. Epclusa Canadian Product Label July 8, 2016 |
| 4. Sarrazin C, et al. 2017. Gastroenterology 152: S1062 |
| 5.FDA Microbiology/Virology Reviews Epclusa_ 208341Orig1s000 (2015) |
